Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022
October 18, 2022 at 06:05 am EDT
Share
Cryo-Cell International, Inc. reported earnings results for the third quarter and nine months ended August 31, 2022. For the third quarter, the company reported revenue was USD 7.68 million compared to USD 7.5 million a year ago. Net income was USD 0.46682 million compared to USD 0.856494 million a year ago. Basic earnings per share from continuing operations was USD 0.06 compared to USD 0.1 a year ago. Diluted earnings per share from continuing operations was USD 0.06 compared to USD 0.1 a year ago.
For the nine months, revenue was USD 22.57 million compared to USD 21.57 million a year ago. Net income was USD 1.93 million compared to USD 2.72 million a year ago. Basic earnings per share from continuing operations was USD 0.23 compared to USD 0.34 a year ago. Diluted earnings per share from continuing operations was USD 0.23 compared to USD 0.33 a year ago.
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
CRYO-CELL INTERNATIONAL, INC. 
